Rare disease Phase 2 startup accelerated by 12 weeks

LyfeSci aligned endpoints and operational planning to shorten startup timelines while maintaining compliance.

A rare disease sponsor needed to accelerate Phase 2 activation while preserving regulatory confidence. LyfeSci reorganized the startup plan to reduce delays.

What we delivered

Compressed site activation timeline through parallel workflows.
Refined endpoint strategy for clear regulatory positioning.
Introduced weekly readiness dashboards for sponsor visibility.

Outcome

The study launched 12 weeks ahead of the original plan with clean documentation and aligned stakeholders.

Ready to apply these insights?

LyfeSci partners with sponsors to translate strategy into execution, from early planning through late-stage delivery.